Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Lymphoma B-cell responsiveness to CpG-DNA depends on the tumor microenvironment
Journal of Experimental and Clinical Cancer Research, Volume 32, No. 1, Article 18, Year 2013
Notification
URL copied to clipboard!
Description
Background: Toll-like receptor (TLR) agonists have important properties that can be exploited for immunotherapy against tumors. Locally injected immunostimulatory oligodeoxynucleotides containing CpG motifs (CpG-ODNs), which are TLR9 agonists, have shown promise in cancer models. Several studies have demonstrated that these motifs have immunologic effects similar to those of bacterial DNA and can stimulate monocytes, macrophages, dendritic, and B cells, which then produce several proinflammatory cytokines. However, these CpG-ODNs appear to produce opposite effects on tumor B cells. Methods. In this study, we investigated the direct effects of a murine class B CpG (1826) ODNs on lymphoma B cells in vitro and in vivo, using mouse models of non-Hodgkin B lymphomas developing in immunoprivileged sites, specifically the brain and the eye, and in subcutaneous sites. Results: In vitro, CpG-ODNs produced antiproliferative and proapoptotic effects on lymphoma B cells. In vivo, it had an antitumor effect when injected into tumors in murine models of subcutaneous lymphoma (SCL) and primary cerebral lymphoma (PCL). However, its intravitreal administration into a primary intraocular lymphoma (PIOL) mouse model did not produce an antitumor effect. In vitro experiments using supernatant from mouse PIOL samples demonstrated that the PIOL molecular microenvironment inhibits the antiproliferative effect of CpG-ODNs on lymphoma B-cells. Conclusions: Responsiveness to CpG stimulation differs in subcutaneous, cerebral, and ocular tumors, according to the tumoral and molecular microenvironment, and this should be considered for further therapeutic approaches. © 2013 Ben Abdelwahed et al.; licensee BioMed Central Ltd.
Authors & Co-Authors
Ben Abdelwahed, Rym
France, Paris
Inserm
France, Paris
Sorbonne Université
France, Paris
Université Paris Cité
Tunisia, Monastir
Faculté de Pharmacie de Monastir
Tunisia, Monastir
Université de Monastir
Cosette, Jérémie
France, Paris
Inserm
France, Paris
Sorbonne Université
France, Paris
Université Paris Cité
France, Paris
Laboratoire Matière et Systèmes Complexes
Donnou, Sabrina
France, Paris
Inserm
France, Paris
Sorbonne Université
France, Paris
Université Paris Cité
France, Evry
Généthon
France, Evry
Approches Génétiques Intégrées et Découvertes Thérapeutiques Pour Les Maladies Rares
France, Evry
Université D'evry Val D'essonne
Crozet, Lucile
France, Paris
Inserm
France, Paris
Sorbonne Université
France, Paris
Université Paris Cité
Ouakrim, Hanane
France, Paris
Inserm
France, Paris
Sorbonne Université
France, Paris
Université Paris Cité
Fridman, Wolf Herman
France, Paris
Inserm
France, Paris
Sorbonne Université
France, Paris
Université Paris Cité
Sautès-Fridman, Catheriné
France, Paris
Inserm
France, Paris
Sorbonne Université
France, Paris
Université Paris Cité
Aouni, Mahjoub
Tunisia, Monastir
Faculté de Pharmacie de Monastir
Tunisia, Monastir
Université de Monastir
Fisson, Sylvain
France, Paris
Inserm
France, Paris
Sorbonne Université
France, Paris
Université Paris Cité
France, Evry
Généthon
France, Evry
Approches Génétiques Intégrées et Découvertes Thérapeutiques Pour Les Maladies Rares
France, Evry
Université D'evry Val D'essonne
Statistics
Citations: 9
Authors: 9
Affiliations: 9
Identifiers
Doi:
10.1186/1756-9966-32-18
e-ISSN:
17569966
Research Areas
Cancer
Genetics And Genomics
Health System And Policy